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Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE)
reuptake inhibitor (SNRI) milnacipran and is currently under development for the treatment of major
depressive disorder. LVM was benchmarked against two other SNRIs, duloxetine and venlafaxine, in
biochemical, neurochemical and pharmacological assays. LVM exhibited high afﬁnity for human NE
(Ki ¼ 92.2 nM) and 5-HT (11.2 nM) transporters, and potently inhibited NE (IC50 ¼ 10.5 nM) and 5-HT
(19.0 nM) reuptake (human transporter) in vitro. LVM had 2-fold greater potency for norepinephrine
relative to serotonin reuptake inhibition (i.e. NE/5-HT potency ratio: 0.6) and 17 and 27 times higher
selectivity for NE reuptake inhibition compared with venlafaxine and duloxetine, respectively. LVM did
not exhibit afﬁnity for 23 off-target receptors. LVM (i.p.) increased cortical extracellular levels of 5-HT,
and NE (minimal effective doses: MEDs ¼ 20 and 10 mg/kg, respectively). In anti-depressive/anti-stress
models, i.p. LVM diminished immobility time in the mouse forced swim (MED ¼ 20 mg/kg) and tail
suspension (MED ¼ 2.5 mg/kg) tests, and reduced shock-induced ultrasonic vocalizations in rats
(MED ¼ 5 mg/kg). Duloxetine and venlafaxine were less potent (MEDs  10 mg/kg). At doses active in
these three therapeutically-relevant models, LVM (i.p.) did not signiﬁcantly affect spontaneous locomotor
activity. In summary, LVM is a potent, selective inhibitor of NE and 5-HT transporters with preferential
activity at the former. It is efﬁcacious in models of anti-depressive/anti-stress activity, with minimal
potential for locomotor side effects.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
About one in every 10 persons is expected to present at least one
depressive episode during his/her lifetime (Andrade et al., 2003;
Kessler et al., 2003). Recent projections for direct and indirect
economic costs position depression near the top of the list for the
year 2030 (Mathers and Loncar, 2006).
Pharmacological management of major depressive disorder
(MDD) remains the cornerstone of treatment. Most effective anti-
depressant agents increase synaptic concentrations of serotonin (5-
HT) and/or norepinephrine (NE) by blocking reuptake of one or
both of these neurotransmitters (Stahl et al., 2005). These treat-
ments include mainly tricyclic antidepressants, selective serotoninþ33 56371 4363.
m (R. Depoortère).
e des Généraux Ricard, 81100
Y-NC-ND license. reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake
inhibitors (SNRIs) and norepinephrine selective reuptake inhibitors
(NRIs). Selective reuptake inhibitors (SSRIs, SNRIs, and NRIs) have
better tolerability than tricyclic antidepressants. In addition, there
is some evidence suggesting the “dual action” of SNRIs may confer
advantages over SSRIs or NRIs in treating MDD symptoms (Stahl
et al., 2005; Papakostas et al., 2007).
Duloxetine, venlafaxine, desvenlafaxine and milnacipran (MLN)
are all SNRIs used to treat MDD; however, only the ﬁrst three are
available in the US. MLN is only marketed as an antidepressant in
Europe and Japan, but is available for the treatment of ﬁbromyalgia
in the US and Australia. SNRIs differ in their relative potency at NE
and/or 5-HT transporters in vitro (and to some extent in vivo).
In vitro, duloxetine, venlafaxine and desvenlafaxine preferentially
inhibit 5-HT reuptake relative to NE reuptake (Bymaster et al.,
2001; Vaishnavi et al., 2004; Deecher et al., 2006); meanwhile,
MLN more potently inhibits NE reuptake relative to 5-HT reuptake
by approximately 2-fold (Moret et al., 1985; Vaishnavi et al., 2004).
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platelets across the clinical dose range, but inhibits NE reuptake (as
measured by the pressor response to intravenous tyramine) only at
higher doses (225 mg/day) (Harvey et al., 2000; Debonnel et al.,
2007). Similarly, duloxetine inhibits 5-HT reuptake at 20 mg/day
(Turcotte et al., 2001) and 60 mg/day (Turcotte et al., 2001; Chalon
et al., 2003) but does not inhibit NE reuptake at these doses (again
using the pressor response to tyramine [Turcotte et al., 2001]).
However, at 60 mg/day duloxetine does increase supine systolic
blood pressure (Turcotte et al., 2001) suggesting it may have some
effects on NE at this dose. Comparable studies with desvenlafaxine
or MLN in human subjects have not been reported in the literature.
Of interest, however, a recent positron emission tomography (PET)
study reported similar occupancy at the norepinephrine (NET) and
serotonin (SERT) transporters (w40% each) in the brain of MDD
patients following 100 mg MLN (Nogami et al., 2012), suggesting it
might block both transporters with equivalent potency at a clini-
cally relevant dose. Unfortunately, PET studies investigating NET
occupancy of venlafaxine, duloxetine, and desvenlafaxine have not
yet been reported in the literature; therefore, comparisons of
relative NET/SERT occupancy across this drug class can not be made
at this time.
It has been proposed that the noted differences in the relative
potency of SNRIs at blocking NET or SERT (in vitro and to some
extent in vivo) may have clinical implications (Stahl et al., 2005;
Shelton, 2009). MDD is a disorder with a broad range of symptoms;
some of which are more associated with NE (attention, working
memory, concentration, alertness, energy and social activity: Saha
et al., 2004; Lapiz and Morilak, 2006; Briley and Moret, 2010;
Kasper et al., 2011), while others are more related to 5-HT (agita-
tion, appetite disturbance, and irritability: Nutt, 2008). Meanwhile,
core symptoms/signs of MDD (depressed mood, sleep disturbance
and anxiety) are attributed to changes in both 5-HT and NE
neurotransmission. Therefore, while SNRIs in general seem to
improve core symptoms of depression, differences in relative po-
tency at NET and/or SERT between SNRIs could contribute to
different levels of efﬁcacy in treating the NE- or 5-HT-related
symptoms of the pathology.
Milnacipran is the only marketed SNRI reported to have greater
relative potency at NET than SERT in vitro and is the ﬁrst SNRI to
report equal occupancy of both transporters at clinical doses. MLN
is a racemic mixture of the 1S, 2R (F2695/levomilnacipran [LVM],
Fig. 1) and 1R, 2S (F2696) enantiomers. In general, enantiomers can
present several advantages over racemates (i.e. the potential for a
less complex, more selective pharmacodynamic proﬁle, an
improved therapeutic index, less complex pharmacokinetic proﬁle,
reduced potential for drug interactions, and less complicated rela-
tionship between plasma concentration and pharmacodynamic
effect: Hutt and Vanetova, 2003). In addition, regulatory guidelines
in the US and Europe recommend development of enantiomers
over racemic drugs where appropriate (FDA guidance, 1992).Fig. 1. Chemical structure of Levomilnacipran (LVM): (1S, 2R)-rel-2-(aminomethyl)-
N,N-diethyl-1-phenyl-cyclopropane-1-carboxamide, a.k.a. F2695.Historical (unpublished) data suggest that LVM is the more active
enantiomer of MLN and LVM is currently in clinical development
for the treatment of MDD.
The object of the present study was 1) to conﬁrm that LVM is the
more active enantiomer of MLN in relevant functional assays and 2)
to characterize in more detail the in vitro and in vivo proﬁle of LVM
relative to two prototypical SNRIs commonly used to treat MDD in
the US, duloxetine and venlafaxine. Thus, a ﬁrst series of in vitro
studies compared MLN and its two enantiomers for binding afﬁnity
at rat and human NET, SERT and DAT, functional potency for NE and
5-HT reuptake inhibition in rat transporters and potentiation of NE-
induced seminal vesicle contraction. The activity of MLN and its
two enantiomers was also compared in vivo in a mouse model of
antidepressant-like activity (forced swim test, FST). Subsequent
studies compared binding afﬁnity of LVM with that of duloxetine
and venlafaxine, at rat and human transporters, and reuptake in-
hibition of [3H] monoamines at rat and human transporters. These
latter in vitro studies were complemented by a microdialysis study
in freely moving rats for measurement of cortical extracellular
levels of monoamines, and behavioral models of depression and
anxiety/stress in mice and rats.2. Materials and methods
2.1. In vitro experiments
2.1.1. Binding afﬁnity assays
All binding assays were performed in 96well plates (DeepWell, Perkin Elmer Life
Sciences, Courtaboeuf, France) in 50 mM TRIS buffer containing 120 mM NaCl and
5 mM KCl (human serotonin transporter [hSERT] and human norepinephrine
transporter [hNET]) or MgCl2 (human dopamine transporter [hDAT]), as described in
the literature (Owens et al., 1997; Millan et al., 2001; Taber et al., 2005). Following
incubation, assay media were rapidly ﬁltered under vacuum through GF/B Uniﬁlter
microplates (presoaked in 0.5% polyethyleneimine), andwashedwith 2 rinses of cold
(4 C) assay buffer using a uniﬁlter apparatus. The radioactivity retained on the ﬁlters
was measured by scintillation spectroscopy using a TopCount radioactivity counter
with 40 ml of scintillation ﬂuid (Microscint 20, Perkin Elmer). See Supplementary
Table 2 for overview of experimental conditions and corresponding references.
2.1.1.1. Human transporters. Radioligand binding was determined in HEK-293 cells
permanently transfected with human SERT, NET, or DAT (65, 70, and 9.2 pmol/mg
protein, respectively). Protein concentrations were determined by the method of
Bradford (1976), using a commercially available kit (Bio-Rad, USA). Membranes were
thawedanddiluted inTRIS buffer to aﬁnal protein concentrationof 3 mgper 400 ml for
SERT and 5 mg per 400 ml for NET and DAT. 50 ml of [3H] citalopram (2 nM, ﬁnal
concentration), [3H]nisoxetine (2 nM), or [3H]WIN35,428 (5 nM) and 50 ml drug/
buffer were added to themembrane/buffer mixture for a ﬁnal assay volume of 500 ml
and incubated for 2 h at room temperature (25 C) for SERT and at 4 C for NET and
DAT. Incubation was terminated by ﬁltration and radioactivity quantiﬁed as stated
above. Non-speciﬁc binding was deﬁned with 10 mM ﬂuoxetine, 10 mM desipramine,
and 10 mM mazindol for SERT, NET, and DAT experiments, respectively. Saturation
binding experiments for SERT and NET were performed with [3H] citalopram (8
concentrations ranging from 0.125 to 16 nM) and [3H]nisoxetine (12 concentrations
ranging from 0.125 to 128 nM), respectively. For DAT, “cold” saturation binding ex-
periments were performed with 5 nM [3H]WIN35,428 and 11 concentrations of
unlabeled WIN35,428 ranging from 0.01 to 10 nM. For competition binding experi-
ments, the binding of 2 nM [3H] citalopram, 2 nM [3H]nisoxetine, or 5 nM [3H]
WIN35,428 was displaced with increasing concentrations of test compound.
2.1.1.2. Rat transporters. Binding assays on rat (r) SERT and rNETwere performed on
membrane preparations from rat brain cortex. Brieﬂy, frozen brains were thawed,
homogenized and centrifuged 3 times in ice cold TRIS buffer containing 120 mM
NaCl and 5 mM KCl (rSERT) or 300 mM NaCl and 5 mM KCl( rNET). Final pellet was
diluted in TRIS buffer to give a ﬁnal concentration of 1.75 mg tissue (based on
original weight) per well, and the binding of 1 nM [3H] citalopram (rSERT) or 2 nM
[3H] N-methyl nisoxetine (rNET) was displaced with increasing concentrations of
test compound. At the end of a 2 h incubation at room temperature (w23 C for
rSERT) or 4 C (rNET), the plates were rapidly ﬁltered and rinsed with ice-cold TRIS
buffer. Non-speciﬁc binding was deﬁned with 0.5 mM paroxetine (rSERT) or 10 mM
desipramine (rNET).
2.1.2. Reuptake assays on human transporters
Experiments were performed on CHO cells stably expressing hSERT, hNET or
hDAT (densities of 623  19, 1272  309 and 897  112 fmol/mg protein,
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1.25 mg/ml geneticin and an antibiotic solution (10,000 units/ml penicillin, 10,000
units/ml streptomycin, 29.2 mg/ml L-glutamine; Invitrogen, Cergy Pontoise, France)
at 37 C in an air/CO2 (95%/5%) water-saturated atmosphere and sub-cultured
weekly. Cells were seeded in opaque 24 well-plates in cell culture medium and
reuptake assays were run once cells reached conﬂuence. The day of the experiment,
cell culture mediumwas removed from the plate, cells were washed once with HBSS
buffer and incubated at room temperature for 5 min in HBSS containing pargyline
(100 mM) and ascorbate (100 mM). Cells were incubated with test compound or no
drug for 15 min before adding [3H]5-HT, [3H]NE or [3H]DA (ﬁnal concentration
10 nM). Following addition of radiolabeled neurotransmitter, cells were allowed to
equilibrate at room temperature for 5 min. Experiments were terminated by rapid
aspiration of reuptake buffer. Cells were carefully and rapidly rinsed once with HBSS
and the cell layer was incubated with Microscint 20 scintillation buffer (300 ml/well;
Perkin Elmer) for at least 2 h under gentle shaking. Radioactivity incorporated in the
cells was determined for each well by liquid scintillation counting using a TopCount
microplate scintillation counter (Perkin Elmer Life Sciences, Courtaboeuf, France).
The non-speciﬁc signal was deﬁned as the radioactivity remaining in the presence of
the selective reuptake blockers ﬂuoxetine (for hSERT; 100 mM), desipramine (for
hNET; 10 mM) or GBR12935 (for hDAT; 10 mM).
Experiments were performed in duplicate or triplicate. [3H]Neurotransmitter
reuptake values were corrected for non-speciﬁc radioactivity incorporation and
expressed as percent of non-treated cells in wells of the same assay plate.
2.1.3. Reuptake assays in rat synaptosomes
Methods differed slightly for the reuptake assays in the initial set of experiments
with MLN, LVM, and F2696 and the second set of experiments with LVM, duloxetine,
and venlafaxine. Most notably, different brain regions were used for synaptosomal
preparation (hypothalamus and cortex/striatum, respectively). The methods for
reuptake assays with MLN, LVM, and F2696 are presented in the Supplementary File.
Procedures for reuptake assays in rat synaptosomes with LVM, duloxetine, and
venlafaxine were as follows.
Rats were killed by decapitation and the brain region (cortex for SERT and NET,
striatum for DAT) was rapidly dissected, weighed and homogenized in 20 vol
(cortex) or 200 vol (striatum) of a 0.32 M sucrose solution using a glass/glass
homogenizer. The homogenate was then centrifuged 10 min at 1000 g at 4 C; the
supernatant was removed and used immediately for the reuptake assay. First,
50 ml of membrane preparation, 350 ml Krebs buffer solution and 50 ml test
compound solution were incubated for 5 min at 37 C. Then, either 50 nM [3H]NE,
10 nM [3H]5-HT, or 25 nM [3H]DA was added to the membrane preparation and
incubated at 37 C for an additional 15, 5, or 4 min, respectively. The incubation
was stopped by addition of 1 ml of ice-cold (4 C) Krebs buffer and rapid ﬁltration
on 24-well plate ﬁlters (Uniﬁlter GF/B). Each well was washed with ice-cold Krebs
buffer. The radioactivity retained on the ﬁlters was measured by liquid scintilla-
tion (Topcount, Perkin Elmer Life Sciences, Courtaboeuf, France) after addition of
scintillation ﬂuid (MicroScint 20, Perkin Elmer, Life Sciences). Non-speciﬁc reup-
take was deﬁned by addition of 10 mM desipramine for [3H]NE, 10 mM citalopram
for [3H]5-HT and 100 mM nomifensine for [3H]DA reuptakes. Results are expressed
as the mean of 3 or 4 EC50 determinations (using one brain homogenate for each
determination).
2.1.4. Seminal vesicle assay
The experimental procedures are essentially the same as those described by
Sharif and Gokhale (1986); details are provided in the Supplementary File.
2.2. In vivo experiments
2.2.1. Animals
Male Sprague-Dawley rats (Iffa-Credo, Les Oncins, France), 180e200 g (USV
experiments) or 240e260 g (microdialysis experiment) at the start of the experi-
ments, were quarantined for 4e5 days. They were then housed 5 to a cage and kept
in temperature- and humidity-controlled rooms (21  1 C, relative humidity:
55  5%) on a 12:12 h light:dark cycle (lights on at 07:00 h). Food (A04 rodent chow,
SAFE, Epinay sur Orge, France) and water were available ad libitum.
Male Swiss miceweighing 18e24 g obtained from the Depre Breeding Center (St.
Doulchard, France) were used in FST studies comparing MLN, LVM, and F2696. OF1
mice (FST), NMRI (TST) and C57Bl6J (locomotor activity), weighing between 20 and
22 g upon arrival, were obtained from Charles River Laboratories France (L’Arbresle,
France) and were used for behavioral studies comparing LVM, duloxetine, and
venlafaxine. All animals were housed in air-conditioned rooms (temperature
21  1 C; humidity 55  5%), with lighting on from 7:00 to 19:00 h.
Animals were handled and cared for in accordance with the Guide for the Care
and Use of Laboratory Animals (Committee for the Update of the Guide for the Care
and Use of Laboratory Animals, 2010). Animals were housed and tested in an As-
sociation for the Assessment and Accreditation of Laboratory Animal Care (AAA-
LAC)-accredited facility in strict compliance with all applicable regulations, and the
protocol was carried out in compliance with French regulations and with local
Ethical Committee guidelines for animal research. All efforts were made tominimize
animal suffering and to reduce the number of animals used.2.2.2. Microdialysis in freely moving rats
On the day before the microdialysis experiment, rats (270e340 g body weight at
the time of surgery) were anaesthetized with isoﬂurane (induction with 4.5%,
maintenance with 2.0%) and positioned in a stereotaxic apparatus (model 900, Kopf
Instruments, USA) with the incisor bar ﬁxed at 3.5 mm. Body temperature was
maintained at 37.5 C with a CMA/150 temperature controller (CMA-Microdialysis
AB, Stockholm). The surface of the skull was exposed, a small hole was drilled
through the bone and the dura was carefully perforated using a 28-gauge syringe
needle. A commercially-available microdialysis probe (CMA/11, CMA-Microdialysis
AB, Stockholm, 3 mm membrane length, 0.24 mm external diameter, in vitro re-
covery rate in the range of 17e20% at ﬂow rate of 2 ml/min at room temperature) was
slowly inserted to terminate in the left medial prefrontal cortex (mPFC), at the
following coordinates: 3.0 mm anterior to bregma, 1.5 mm lateral to the midline
suture, 4.5 mm ventral from the dura, at a medially-directed vertical angle of 14 .
The probes were anchored to the skull with three stainless steel screws and dental
acrylic cement. Following recovery from anesthesia, rats were transferred to bowl-
shaped Perspex microdialysis cages (CMA-Microdialysis AB, Stockholm) with free
access to food and water, and the probes were connected via a liquid swivel and
counterbalance arm assembly to perfusion syringes containing ﬁltered degassed
Ringer’s solution (composition in mM: NaCl, 147; KCl, 4.0; CaCl2, 2.4). The probes
were perfused at a rate of 0.2 ml/min overnight. The following morning, the perfu-
sion syringes were reﬁlled with fresh degassed Ringer’s and the pump infusion rate
was increased to 2.0 ml/min. After a 2-h equilibration period, microdialysate samples
were collected in glass microtubes containing 15 ml of HCl (0.05 N) þ EDTA (1 mM)
using refrigerated microfraction collectors (Univentor model 820).
Immediately following the collection of four 30-min samples for measurement
of pre-treatment “baseline” levels of monoamines, test compounds or saline (0.9%
NaCl) was administered i.p. (10 ml/kg body weight), and microdialysate samples
were collected continuously over the next 4 h. At the end of the experiment, rats
were decapitated and the brains removed, cooled on ice and cut into coronal sec-
tions with the aid of a stainless steel brain matrix. Probe placement was veriﬁed by
visual inspection of the probe tract in the tissue slices (which, although not as
precise as veriﬁcation following ﬁxation of tissue, is deemed sufﬁcient when large
brain structures are targeted).
Each acidiﬁed microdialysate sample was divided into 2 aliquots for parallel
analyses by 2 independent HPLC systems, one optimized for the quantiﬁcation of NE
and one optimized for 5-HT and DA levels.
NE in acidiﬁed microdialysate sample aliquots (30 ml) was derivatized and
quantiﬁed by HPLC with ﬂuorescence detection as described by Yoshitake et al.
(2003). This method is based on precolumn derivatization of NE with benzyl-
amine that results in a highly ﬂuorescent and stable benzoxazole derivative. Brieﬂy,
30 ml of a derivatizing reagent mixture containing benzylamine HCl (33 mM), CAPS
buffer (3-cyclohexyl-aminopropanesulfonic acid, 25 mM) and potassium hex-
acyanoferrate(III) (0.55 mM) in 83% methanol were added to 30 ml of acidiﬁed
microdialysate sample. Samples were capped, mixed and incubated for 20 min at
50 C, and loaded into a HPLC system (WATERS 2690 Alliance Separation Module)
equipped for programmed autoinjection (8 C). Chromatographic conditions con-
sisted of a C18 reverse-phase column (WATERS Symmetry Shield 2.1150mm, 5 mm
particle size) maintained at 30 C. A gradient mobile phase (ﬁnal pH 4.5) consisted of
sodium acetate (15 mM), EDTA (0.5 mM) and acetonitrile (30e90% vol/vol), and was
delivered at a constant ﬂow rate of 0.4 mL/min. Fluorescent derivatives were
detected with a Waters Model 474 scanning ﬂuorescence detector (lex ¼ 345 nm,
lem ¼ 480 nm). Detector signal output was acquired and analyzed with chroma-
tography application software (Empower Chromatography Manager, Waters).
DA and 5-HT in acidiﬁed sample aliquots (30 ml) were quantiﬁed directly by HPLC
coupled with electrochemical detection. Samples were loaded into a HPLC system
(WATERS 2690Alliance SeparationModule) equipped for programmed auto-injection
(8 C). Chromatographic conditions consisted of a cationic exchange column (Eicom
CAX, 2.0 200mm,5mmparticle size)maintained at40 C. Themobile phase (ﬁnalpH
6.2) consisted of sodium phosphate C2H7NO2 (100 mM), Na2SO4 (50 mM), EDTA
(0.125mM), KCl (8mM)and25%methanol, andwasdelivered at a constantﬂowrate of
0.30mL/min. Detectionwas performedwith aWATERS 2465 electrochemical detector
equipped with a glassy carbon working electrode set at an oxidation potential
of þ0.430 V. Detector signal output is acquired and analyzed with chromatography
application software (Empower ChromatographyManager, Waters). Quantiﬁcation of
chromatographic peaks was based on the comparisonwith calibration curves derived
from authentic standards of NA, 5-HT and DA prepared in acidiﬁed Ringer’s solution
and carried through the respective analytical procedure. Blanks consisted of Ringer’s
solution that were recovered from the infusion syringes at the end of the experiment,
acidiﬁed and carried through the respective analytical procedure.
Monoamine levels in the microdialysate samples were calculated as absolute
amount (fmoles) per 30 ml injected aliquot, and were expressed as a percentage of
“baseline” values, deﬁned here as the average amount of monoamine measured in
the 4 microdialysate samples preceding the intraperitoneal administration of drug
or saline solutions.
2.2.3. Forced swimming test (FST)
Both sets of FST experiments (those comparing MLN, LVM, and F2696 and those
comparing LVM, duloxetine, and venlafaxine) were conducted using the same
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water, and the observation periodwas 5min for theMLN, LVM, F2696 study. The rest
was similar to the procedure described below for the study comparing LVM to
duloxetine and venlafaxine.
Experimentally naïve mice were injected with vehicle or test compound i.p.
(10 ml kg/kg) and placed individually 30 min later into a glass cylinder (height:
24 cm, diameter: 13 cm) containing 10 cm of water (22  0.5 C) for 6 min. The
latency time to the ﬁrst bout of immobility was recorded starting immediately after
placing the mouse in the cylinders (precision 0.1 s). During the last 4 min, the
duration of immobility was also measured (precision 0.1 s). A mouse was judged
immobile when it ceased all active behaviors (i.e. struggling, swimming, jumping)
and remained passively ﬂoating in the water or made minimal movements neces-
sary to maintain its nostrils above water.
Note: Mice were utilized in the FST experiments as they are more sensitive than rats
to the acute effects of SNRIs and SSRIs in this model (Castagne et al., 2009; in-house
unpublished data). Also, the use of mice in this test presents the advantage of having
the same species run in the two “depression” models (FST and tail suspension test
[TST]). The same experimenter performed the FST and TST, and experiments were
performed under blind conditions.
2.2.4. Tail suspension test (TST)
Movements of experimentally naïve mice, individually suspended by the tail
(2 cm from the tip) to a vertical tail hanger (18 cm from the ﬂoor), were recorded by
an automated animal activity monitor (Med Associates, Inc, Georgia, USA). The
duration of immobility, deﬁned as the time that mice no longer exhibit escape-
oriented behaviors, was recorded during a 6 min test session. The animals were
administered either with an injection of saline or test compound i.p. (10 ml/kg), and
returned to their individual home cages for 30 min before being tested in the tail
suspension chamber.
2.2.5. Stress-induced ultrasonic vocalization (USV)
The procedure was carried out as described in details by Bardin et al. (2010).
Succinctly, rats were trained to associate unavoidable scrambled foot-shocks (si-
nusoidal, 0.4 mA, 1 s duration) to a conditioned light stimulus. During the test
sessions, rats were injected i.p. (10 ml/kg) with drug or vehicle, 30 min before being
placed into the cage for automatic recording of the time spent emitting ultrasonic
vocalization calls (around 22 kHz) using the UltraVox system (Noldus, Wageningen,
The Netherlands). During these test sessions, only the ﬁrst foot shock was delivered
with the conditional stimulus; subsequently, only the conditional stimulus was
presented.
2.2.6. Spontaneous locomotor activity
Locomotor activity was recorded by an automated animal activity monitor
(Multivarimex, Columbus Instruments, Columbus, Ohio, USA), by counting in-
terruptions of at least 0.1 s of two parallel, horizontal infrared beams positioned
2 cm above the ﬂoor of the cage and spaced 7.5 cm apart. Experimentally naïve mice
were injected with test compound (i.p. 10 ml/kg) and put back in their home cage
during 30 min. Immediately thereafter, mice were placed in an acrylic
(22  8.5  18 cm, L  W  H) cage without sawdust positioned in the activity
monitor for recording of their spontaneous locomotor activity (number of inter-
rupted light beams) during 60 min.Table 1
Comparative afﬁnities of milnacipran and its enantiomers at human recombinant
and rat native transporters.
Milnacipran LVM (F2695) F2696
Human
SERT 16.9  1.3 11.2  0.3 290  40
NET 139  24 92.2  11.9 >104
DAT >104 >104 >104
Rat
SERT 16.0  1.7 7.6  1.5 1960  218
NET 34.3  1.7 11.4  0.9 124  20
Numbers represent the average S.E.M. Ki (nM); all experiments were performed in
triplicate except hNET and hDAT experiments with F2696 (5 determinations), and
rSERT with F2696 (4 determinations). Data for rat DAT not available.2.3. Statistical analysis
Binding studies were analyzed using built-in equations from the non-linear
regression program Prism v4.03 (GraphPad Software, San Diego, CA, USA). Inhibi-
tion constants (Ki) were calculated from estimates of concentrations required to
inhibit binding by 50% (IC50) using the built-in “Chen-Prusoff approximation”:
Ki ¼ IC50=ð1 ð½LIGAND=KDLIGANDÞÞ:
KD values for [3H] citalopram: 3.2 (hSERT) and 0.48 nM (rSERT); [3H] N-methyl
nisoxetine: 8.5 (hNET) and 0.62 nM (rNET); and [3H]WIN35,428: 43 nM (hDAT).
In vitro reuptake inhibition data (human) were analyzed by non-linear regres-
sion to determine an IC50; concentration-response data (rat) were analyzed ac-
cording to a 4-parameter sigmoid curve ﬁt logistic model to determine an IC50.
(Prism v4.03 software).
In vitro seminal vesicle assay data were analyzed by a one-way ANOVAwith the
concentration as the between-subjects factor, followed by a HolmeSidak post-hoc
test for comparison with the appropriate control group.
Microdialysis datawere analyzed using a one-way ANOVAwith the treatment as
the between-subjects factor, followed if appropriate by a HolmeSidak post-hoc test
for comparison with the appropriate vehicle-treated group (for NE and 5-HT mea-
sures collated across t0e240 post-injection). In addition, for the time-course analysis,
NE 5-HT and DA measures were analyzed using a two-way ANOVA with the treat-
ment as the between-subjects and time as the within-subject factors, followed if
appropriate by a one-way ANOVA for post-hoc comparisons with the vehicle-
injected group.For behavioral studies, datawere analyzedwith a one-way ANOVAwith the dose
as the between-subjects factor, followed by a HolmeSidak post-hoc test for com-
parison with the appropriate vehicle-treated group. ANOVAs were run with the
Sigmastat 3.5 software (Systat software, Inc., Point Richmond, CA, USA).2.4. Drugs
LVM and venlafaxine were synthesized in-house. Duloxetine was obtained from
Sigma RBI or Bepharm (Shangai, China). [3H] Citalopram (TRK1068; 70e90 Ci/mmol)
and [3H]nisoxetine (TRK942; 70e90 Ci/mmol) were purchased from GE-Healthcare
(Orsay, France). [3H]WIN35,428 (NET1033; 70e90 Ci/mmol) was obtained from
Perkin-Elmer (Courtaboeuf, France). [3H]DA (NET673, speciﬁc activity: 30e60 Ci/
mmol) and [3H]NE (NET377, speciﬁc activity: 10e30 Ci/mmol) were purchased
from Perkin Elmer. [3H]5-HT triﬂuoroacetate (TRK1006, speciﬁc activity: 80e130 Ci/
mmol) was purchased from GEHealthcare. Desipramine hydrochloride was pur-
chased from Sigma-RBI (St Quentin-Fallavier, France); citalopram was a gift from
Lundbeck.
All drugs were dissolved in ultrapure water (binding assays, rat reuptake inhi-
bition assays), or DMSO (human reuptake inhibition assays). In behavioral experi-
ments, doses (expressed as theweight of the free base) were adjusted on the basis of
body weight measured on the day of administration; control animals received
vehicle (saline). The treatments were administered under blind conditions.3. Results
3.1. Conﬁrmation that LVM is the pharmacologically more active
enantiomer of milnacipran
LVM exhibited high afﬁnity for NET and SERT in native rat (r)
tissue (Ki ¼ 11.4 and 7.6 nM, respectively) and human (h) recom-
binant NET and SERT (Ki ¼ 92.2 and 11.2 nM, respectively). All these
afﬁnities were slightly higher than those of MLN, and at least 10
times higher than those of F2696 (Table 1). None of the three
compounds had detectable afﬁnity for hDAT (Ki > 10 uM; rDAT not
tested). In pharmacodynamic models, LVM, compared to F2696,
was 50 and 13 times more potent in inhibiting NE and 5-HT re-
uptake in rat hypothalamic synaptosomes. All three compounds
signiﬁcantly (all F’s > 3.2, all p’s  0.01) potentiated NE-induced
contraction of rat seminal vesicles in vitro, but LVM was 300
times more potent than F2696. Lastly, there was a signiﬁcant effect
in the forced swim test (FST) in mice (F(6,42)¼ 56.9, p< 0.001), but
again, LVM was 33 times more potent than F2696 (Table 2). In the
latter two models, LVM was also more potent than MLN, albeit less
so than F2696. Collectively, these data conﬁrm previous unpub-
lished data suggesting that LVM is the more pharmacologically
active enantiomer of MLN.3.2. In vitro proﬁle of LVM compared to duloxetine and venlafaxine
Having conﬁrmed that LVM is the more active enantiomer of
MLN, a second set of studies was performed to further characterize
the pharmacological proﬁle of LVM relative to two prototypical
SNRIs currently used to treat MDD, duloxetine and venlafaxine.
Table 2
Comparison of activity of milnacipran (MLN), LVM and its 1R, 2S enantiomer F2696
in pharmacodynamic models related to the norepinephrine or serotonin systems.
MLN LVM F2696
Inhibition of [3H] monoamine
reuptake, rat hypothalamus
synaptosomes (IC50, nM)
NE 30 15 750
5-HT 150 46 600
Potentiation of NE-mediated
contraction of rat seminal
vesicle (MEC, mM)
0.1 0.1 30
Reduction of immobility time,
FST in mice (MED, mg/kg i.p.)
10 3 100
5-HT ¼ 5-hydroxytryptamine; ED50 ¼ median effective dose; FST ¼ forced swim
test; IC50 ¼ median inhibitory concentration; MEC ¼ minimum effective concen-
tration; NE ¼ norepinephrine; PFC ¼ prefrontal cortex.
N ¼ 4 for the reuptake assay, 5e7 for the vesicle model, and 10 for the FST.
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A.L. Auclair et al. / Neuropharmacology 70 (2013) 338e347342LVM has selective afﬁnity for SERT and NET, with a potency in-
between that of duloxetine and venlafaxine.
Duloxetine had higher afﬁnity for r and h SERTand NET than LVM,
while venlafaxine exhibited low afﬁnity for both h and r NET. Dulox-
etine also showedmodest afﬁnity (Ki¼ 446 nM) for DAT, but LVMand
venlafaxine had no appreciable afﬁnity for this transporter (Table 3).
LVM did not exhibit afﬁnity (Ki  10 mM) for any of the 23 other
targets tested; venlafaxine was similarly devoid of afﬁnity for these
targets. Duloxetine showed rather weak afﬁnity (Ki ranging from
0.24 to 0.65 mM) for some targets (i.e. 5-HT, dopamine D3 and
histamine H1 receptors; Supplementary Table 2).
3.3. LVM is a norepinephrine-preferring SNRI in functional assays
In CHO cells stably expressing transfected human transporters,
LVMreduced the reuptakeof [3H]NEand [3H]5-HT ina concentration-
dependent manner (Fig. 2, top panel), with approximately two-fold
higher potency at NET (IC50 ¼ 10.5 and 19.0 nM, for [3H]NE and [3H]
5-HT, respectively) (Table 4). Thus, LVMhad anNE/5-HT potency ratio
of 0.6. LVM did not reduce the reuptake of [3H]DA (IC50 > 100 mM),
consistentwith its veryweak afﬁnity for the DAT. In native tissue (rat
synaptosomes), LVM inhibited [3H]NE and [3H]5-HT reuptakewith an
IC50 of 62.2 and 72.6 nM, respectively. LVM was much less potent in
inhibiting [3H]DA reuptake (Table 4).
In contrast, both duloxetine and venlafaxine inhibited [3H]5-HT
reuptake more potently than that of [3H]NE at human transporters
(NE/5-HT reuptake selectivity ratios of 16 and 10, respectively)
(Fig. 2, middle and bottom panels, and Table 4), and interfered with
DA reuptake to some extent (IC50: 2.6 and 22.7 mM, for duloxetine
and venlafaxine, respectively). Similarly, in rat synaptosomes,
duloxetine and venlafaxine blocked 5-HT reuptake withw10 times
greater potency than NE reuptake (duloxetine: IC50 ¼ 10 andTable 3
Afﬁnities at human recombinant and rat native transporters.
LVM Duloxetine Venlafaxine
Human
SERT 11.2  0.3 0.2  0.0 17.9  2.5
NET 92.2  11.9 8.9  0.8 >104
DAT >104 446  31.1 >104
Rat
SERT 7.6  1.5 0.3  0.0 20.6  2.4
NET 11.4  0.9 2.0  0.2 1187  317
Numbers represent the average S.E.M. Ki (nM); all experiments were performed in
triplicate except hSERT and hNET experiments with duloxetine (6 determinations),
hNET experiments with venlafaxine (6 determinations), and hSERTwith venlafaxine
(5 determinations). Data for rat DAT not available.
Note: the LVM data presented in this table are the same as those presented in
Table 1, but are provided here for the sake of facilitating comparison to duloxetine
and venlafaxine.
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Fig. 2. Effects of LVM, duloxetine and venlafaxine on reuptake of [3H]5-HT [3H]
norepinephrine (NE) and [3H]dopamine (DA) in CHO cells stably expressing human
SERT, NET or DAT. Symbols are mean  SEM. N ¼ 2e3 determinations per point.90.7 nM, respectively; venlafaxine: IC50 ¼ 75.8 and 726.3 nM,
respectively) and had modest effects on DA reuptake (IC50 ¼ 402.4
and 5270 nM for duloxetine and venlafaxine, respectively).
Amongst 6 other reference antidepressants tested under the
same experimental conditions (SSRIs: escitalopram and cit-
alopram; SNRIs: duloxetine, venlafaxine; NARI: reboxetine; TCA:
desipramine; data on ﬁle), LVM is the only compound showingw2-
fold preferential NET over SERT blocking capacities (based on
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Fig. 3. Summary of selectivity ratios of reuptake potencies using human (h) trans-
porters. Ratios were calculated by dividing IC50 (potency in reuptake assays) for NET by
that for SERT, for LVM and a host of comparators.
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Fig. 4. Effects of LVM, duloxetine and venlafaxine on extracellular levels of 5-HT and
NE in the medial prefrontal cortex of freely moving rats. Bars are mean þ SEM of the %
amount of neurotransmitter versus baseline (4 samples collected before test com-
pound or vehicle injection) averaged from t0 to t240 min post-injection. N ¼ 14e15 for
vehicle and 6e7 per dose for LVM; n ¼ 6e7 rats for vehicle and per dose for duloxetine
and venlafaxine. **p < 0.01 compared to corresponding vehicle, HolmeSidak post-hoc
test following signiﬁcant one-way ANOVA.
A.L. Auclair et al. / Neuropharmacology 70 (2013) 338e347 343uptake assays on transfected human transporters: Fig. 3). Indeed,
the NE/5-HT selectivity ratio of LVM is approximately 27 and 17
times that of duloxetine and venlafaxine, respectively.
3.4. LVM augments fronto-cortical extracellular levels of 5-HT, NE
and DA
LVM signiﬁcantly augmented extracellular levels of both 5-HT
and NE (F(4,38) ¼ 8.90, p < 0.001, and F(4,40) ¼ 14.54, p < 0.001,
respectively) in the frontal cortex of rats (Fig. 4). LVM increased NE
levels more potently than those of 5-HT (MED ¼ 10 and 20 mg/kg,
respectively). At the lowest dose found to signiﬁcantly increase NE
or 5-HT levels in the prefrontal cortex (10 mg/kg), the ratio of NE/5-
HT (percent increase) was approximately 4. At higher doses, this
ratio was approximately 1 (Table 5).
Duloxetine also signiﬁcantly increased NE and 5-HT in the rat
mPFC (F(3,26) ¼ 4.44, p ¼ 0.01, and F(3,26) ¼ 11.54, p < 0.001, for 5-
HTand NE, respectively). Duloxetine signiﬁcantly increased NE at all
doses tested, and signiﬁcantly increased 5-HT at 10 mg/kg with a
(non-signiﬁcant) tendency toward increase at 20 and 40 mg/kg
(Fig. 4). The ratio of NE/5-HT (percent increase) was approximately 1
at all doses tested; except the 20 mg/kg dose (ratio ¼ 1.6) (Table 5).
Venlafaxine signiﬁcantly increased extracellular levels of both
catecholamines aswell (F(4,33)¼ 4.33, p< 0.001, and F(4,32)¼ 24.3,
p < 0.001, for 5-HT and NE, respectively). Venlafaxine was 4 times
more potent at increasing 5-HT levels versus NE (MED 2.5 andTable 4
Effects on uptake of norepinephrine, serotonin and dopamine using human trans-
porters transfected in CHO cells, or rat synaptosomes.
NE 5-HT DA
Human
LVM 10.5  0.9 19.0  3.9 >100,000
Duloxetine 11.2  2.1 0.7  0.0 2577  205.6
Venlafaxine 449  43.6 45.1  1.3 22,663  7374
Rat
LVM 62.2  8.7 72.6  19.2 40,840  5328
Duloxetine 90.7  16.2 10.0  1.1 402.4  42.4
Venlafaxine 726.3  150.9 75.8  17.8 5270  372
Numbers represent the average  S.E.M. IC50 (nM), for blockade of norepinephrine
(NE), serotonin (5-HT) and dopamine DA; all experiments were performed in trip-
licate except for LVM human DA (2 determinations), duloxetine rat NE and 5-HT,
and venlafaxine rat 5-HT (4 determinations).10 mg/kg, respectively) (Fig. 4). The ratio of NE/5-HT (percent in-
crease) was notably below 1 at doses lower than 10mg/kg (Table 4).
Time-course data for NE and 5-HT extracellular levels are
available in Supplementary Fig. 1, along with those for DA. All three
SNRIs dose-dependently increased NE, 5-HT and DA in the rat
prefrontal cortex. LVM augmented extracellular levels of DA start-
ing from 10mg/kg i.p. Venlafaxine showed an activity proﬁle on the
whole similar to that of LVM, although theMEDwas higher (40 mg/
kg). There was a muchmore robust effect of duloxetine on DA, with
levels reaching a peak of 10 times that of baseline 60 min post in-
jection at 40 mg/kg.3.5. LVM produces antidepressant-like effects in the forced swim
and tail suspension tests in mice comparable to that of duloxetine
and venlafaxine
Following injection of vehicle, mice spent time in immobility
with average values that were homogenous across the different sets
of forced swim experiments (from 165.7  20.7 to 169.0  18.7 s)
(Fig. 5, white bars, left panels). LVM, duloxetine, and venlafaxine all
dose-dependently and signiﬁcantly decreased immobility relative
to vehicle (F(4,34) ¼ 5.5, p < 0.01; F(3,24) ¼ 21.0, p < 0.001, and
F(3,27) ¼ 3.7, p < 0.05, respectively) with MEDs of 20 mg/kg i.p
(Fig. 5). At the highest dose tested (40 mg/kg), the maximal
decrease in immobility time was 78%, 69% and 52%, for duloxetine,
LVM and venlafaxine respectively.
In the mouse tail suspension test, following injection of vehicle,
mice spent from 124.0  16.4 to 152.5 12.8 s in immobility (Fig. 5,
white bars, middle panels). LVM and duloxetine signiﬁcantlyTable 5
Ratios of NE/5-HT efﬁcacy based on microdialysis data.
0.63 mg/kg 2.5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg
LVM e Nc 4.0 0.9 1.0
Duloxetine e e 0.9 1.6 1.3
Venlafaxine Nc 0.2 0.6 e 1.5
Ratios were calculated as follows:
ðaverage % increase for the given dose average % increase for vehicleÞ for NE
ðaverage % increase for the given dose average % increase for vehicleÞ for 5 HT
for data collected at t0e240 post-injection. e: not tested; Nc: not calculated, the
increase being not signiﬁcant at these doses.
Table 6
Effects on spontaneous locomotor activity.
Veh 2.5 mg/kg 10 mg/kg 40 mg/kg
LVM 174.0  23.3 169.0  45.1 166.7  22.8 174.0  26.2
Duloxetine 244.4  34.1 253.6  40.2 182.1  25.3 44.6  9.3**
Venlafaxine 189.8  32.5 229.0  28.4 251.3  29.6 308.7  35.0
Numbers represent the average  S.E.M. value (arbitrary units). Locomotor activity
was recorded for 1 h, 30 min following i.p. administration of compounds or vehicle
(Veh). **p < 0.01, compared with vehicle, HolmeSidak post-hoc test following
signiﬁcant one-way ANOVA. For LVM: N ¼ 11 for vehicle and 7 per dose; for
duloxetine:N¼ 12 for vehicle and 7 per dose; for venlafaxine:N¼ 11 for vehicle and
7 per dose.
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Fig. 5. Effects of LVM, duloxetine and venlafaxine in the forced swim test (FST) or tail suspension test (TST) in mice, and ultrasonic vocalization (USV) model in rats. Bars are
mean  SEM. Compound or vehicle (Veh) was administered i.p. 30 min before the test. *p < 0.05, **p < 0.01, ***p < 0.001, versus saline, HolmeSidak post-hoc test following
signiﬁcant one-way ANOVA. For FST: N ¼ 8e10 for vehicle and 7e8 per dose; for TST: N ¼ 11e14 for vehicle and 7e9 per dose; for USV: N ¼ 7e12 for vehicle and 9 per dose. Doses
are in mg/kg i.p.
A.L. Auclair et al. / Neuropharmacology 70 (2013) 338e347344decreased immobility relative to vehicle (F(4,45) ¼ 5.7, p < 0.001
and F(4,42)¼ 11.8, p< 0.001, respectively) with a MED of 2.5 mg/kg
i.p. and 10 mg/kg i.p, respectively. There was a trend toward
reduced immobility with venlafaxine, but this effect was not sta-
tistically signiﬁcant (F(4,34) ¼ 2.2, n.s.). LVM reduced immobility in
a U-shaped manner, not observed for duloxetine or venlafaxine.
3.6. LVM has anti-stress/anxiolytic activity in the USV model in rats
Under control (vehicle injection) conditions, rats emitted USV
for an average of 173.2  24.5 to 204.0  33.5 s (Fig. 5, white bars,
right panels). LVM and duloxetine signiﬁcantly and dose-
dependently reduced USV (F(3,36) ¼ 6.5, p < 0.001 and
F(3,33)¼ 5.9, p< 0.01, respectively). The MED for LVMwas 5mg/kg
i.p and that for duloxetine was 20mg/kg i.p. Venlafaxine (5e20mg/
kg) did not signiﬁcantly modify the time spent emitting USV
(F(3,36) ¼ 0.3, ns).
3.7. LVM does not modify spontaneous locomotor activity of mice
LVM did not signiﬁcantly modify spontaneous locomotion
(F(3,28) ¼ 0.02, n.s.), with values at all doses remarkably close tothose of its control group (differing by less than 5%) (Table 6).
By contrast, duloxetine signiﬁcantly reduced locomotor counts
(F(3,29)¼ 8.15, p< 0.001), with amarked reduction (82%) at 40mg/
kg. Although venlafaxine tended to increase spontaneous locomo-
tor activity (62% at 40 mg/kg), the effect was not signiﬁcant
(F(3,28) ¼ 2.44, n.s.).
On thewhole, in rodentmodels of depression/stress, LVMwas at
least as potent as duloxetine and venlafaxine, albeit slightly less
efﬁcacious than the former in the TST model. Additionally, efﬁcacy
Table 7
Summary of pharmacological activity of LVM and its comparators in behavioral
models.
LVM Duloxetine Venlafaxine
Therapeutically relevant
models
FST 20 20 20
TST 2.5a 10 >40
USV 5 20 >40
Model related to unwanted
side-effects
Spontaneous
locomotion
>40 40 >40
Numbers indicate minimal effective dose, in mg/kg, i.p.
FST: forced swim test, TST: tail suspension test, USV: ultrasonic vocalization test.
a Partial effect at higher dose.
A.L. Auclair et al. / Neuropharmacology 70 (2013) 338e347 345of LVM in the FST, TST, and USV assays was observed at doses that
did not produce sedation (Table 7).
4. Discussion
This is the ﬁrst paper to characterize the in vitro and in vivo
pharmacological proﬁle of the new SNRI LVM. Two sets of data are
presented in this manuscript: 1) initial pharmacological studies
comparing milnacipran and its two enantiomers LVM (F2695) and
F2696 and 2) more detailed pharmacological studies characterizing
the in vitro and in vivo pharmacological proﬁle of LVM relative to
two prototypical SNRIs, duloxetine and venlafaxine.
The initial pharmacological studies presented in this manuscript
conﬁrmed LVM as themore pharmacologically active enantiomer of
milnacipran, and provide a rationale for why levomilnacipran was
selected for development for the treatment of MDD in the US.
The focus of this manuscript was to characterize the in vitro and
in vivo pharmacological proﬁle of LVM relative to duloxetine and
venlafaxine, two SNRIs currently marketed as antidepressants. In
this manuscript, we show that LVM binds with high afﬁnity to
human and rat NET and SERT in vitro (but lacks afﬁnity for DAT).
Neither LVM, duloxetine, nor venlafaxine had signiﬁcant afﬁnity for
any of the 23 off-target receptors tested (including those associated
with side-effects: muscarinic M1, M3, 5-HT2B, m opioid, adrenergic
a1, a2). However, duloxetine did show sub-micromolar afﬁnity for 7
targets. Furthermore, LVM, duloxetine, and venlafaxine all potently
inhibit NE and 5-HT reuptake in vitro (for both species).
Relative to the other SNRIs tested, LVM has less absolute afﬁnity
for NET and SERT than duloxetine (6e56 fold, depending on the
transporter and the species [human or rat]), but quite similar
afﬁnity for h and r SERT (around 2 fold) and greater afﬁnity for
NET (at least 100 fold) than venlafaxine. However, in terms of
functional potency in vitro (reuptake inhibition), LVM has similar
potency to duloxetine for NE reuptake (both species), but lesser
potency for 5-HT reuptake (7 and 27 fold less, for rat and human
transporters, respectively). Interestingly though, in the mice FST
assay, LVM was as efﬁcacious and potent as duloxetine, and even
more potent in the rat USV model, which would suggest the
importance of the NE system in the activity of compounds in these
two models.
In terms of relative afﬁnity (NET/SERT afﬁnity ratio), LVM pre-
sents a more balanced afﬁnity for NET versus SERT (NET/SERT ratio
around 1.5 and 8 for rat and human transporter) than either
duloxetine (ratio around 7 and 45) or venlafaxine (ratio around 58
and above 500). Interestingly, in vitro LVM more potently inhibits
NE than 5-HT reuptake (NE/5-HT ratio 0.9 and 0.6 for rat and hu-
man transporter, respectively) which is in contrast to duloxetine or
venlafaxine which more potently inhibit 5-HT than NE reuptake
(NE/5-HT ratio of 9 and 16 for duloxetine at rat and human trans-
porters and 9.5 and 10 for venlafaxine at rat and human trans-
porters). The NE/5-HT reuptake inhibition ratios reported here for
duloxetine and venlafaxine are consistent with those of previousreports (Wong, 1998; Bymaster et al., 2001; Vaishnavi et al., 2004),
and the NE/5-HT ratios reported here for LVM are similar to those
previously reported for milnacipran (Vaishnavi et al., 2004).
Differences in NE/5-HT reuptake inhibition ratios amongst
SNRIs may have clinical relevance (Stahl et al., 2005; Shelton, 2009;
Blier and Briley, 2011; Kasper et al., 2011). For example, different
potencies at NET and SERT in vivo could contribute to relative ef-
ﬁcacy in treating different MDD symptoms associated with either
NE (e.g. attention, working memory, concentration, alertness, en-
ergy and social activity) (Lapiz andMorilak, 2006; Briley andMoret,
2010; Kasper et al., 2011) or 5-HT (e.g. agitation, appetite distur-
bance, and irritability) (Nutt, 2008). In fact, some clinical data
suggest MLN (which has a comparable in vitro proﬁle to LVM) offers
some beneﬁt in terms of treating the noradrenergic symptom
cluster (Blier and Briley, 2011; Kasper et al., 2011). Similar clinical
data have been generated with LVM (publications in preparation).
Of note, LVM binds with higher afﬁnity to SERT than NET (NET/
SERT afﬁnity ratio of 8 and 1.5 for human and rat respectively), but
more potently inhibits NE relative to 5-HT reuptake (NE/5-HT po-
tency ratio of 0.6 and 0.9 in human and rat, respectively). Reasons
for this discrepancy between NET/SERT afﬁnity ratios and NE/5-HT
potency ratios are unclear, but similar disparities between binding
and reuptake data have been reported for milnacipran as well as
other SNRIs, SSRIs or TCAs (Vaishnavi et al., 2004; Stahl et al., 2005;
in house data). This discrepancy may be due to the fact that [3H]
nisoxetine labels a site which may only partially overlap the
endogenous ligand site, as suggested by Zhen et al. (2012). Thus, the
potency to displace [3H]nisoxetine binding may be an underesti-
mate of the actual potency to block the reuptake of [3H]NE.
Rat microdialysis studies were conducted to determine if the
observed differences in potency at NET and SERT in vitro translated
to differences in potency in vivo. In the present study, LVM,
duloxetine, and venlafaxine signiﬁcantly increased extracellular
concentrations of NE and 5-HT in the rat prefrontal cortex.
Observed effects of duloxetine and venlafaxine are consistent with
previous reports (Kihara and Ikeda, 1995; Koch et al., 2003; Beyer
et al., 2002). Furthermore, at the lowest effective dose of LVM
(10mg/kg), therewas a signiﬁcant increase in NE, but not 5-HT (NE/
5-HT ratio of w4). At subsequent doses (20 and 40 mg/kg), LVM
increased NE and 5-HTconcentrations with equal efﬁcacy (NE/5-HT
ratio of w1 at both doses). Although not deﬁnitive, these data
suggest that LVM may have a greater impact on extracellular NE
levels than 5-HT levels at lower doses, but at higher doses, LVMmay
affect both catecholamines equally. It is unclear if similar effects
would be observed in other brain regions, or if this greater potency
at NET would be sustained following chronic administration;
however, these data (in combination with the in vitro data above)
suggest LVM may differ from other SNRIs in terms of relative po-
tency at NE versus 5-HT in vitro and in vivo.
The effects of LVM on extracellular levels of NE and 5-HT are in
contrast to those of venlafaxine, which more potently increased
concentrations of 5-HT relative to NE (MEDs of 2.5 and 10mg/kg for
NE and 5-HT, respectively; NE/5-HT ratio of 0.2 and 0.6, respec-
tively). Ratios for venlafaxine reported in the present microdialysis
study are contrary to previously reported data showing signiﬁcant
increases in NE and 5-HT in the rat prefrontal cortex following 5,15,
and 40mg/kg venlafaxine ip (Koch et al., 2003) or equal increases in
NE and 5-HT following 10 mg/kg ip (Weikop et al., 2004). However,
the observed ratios in the present study are consistent with data in
human subjects suggesting that venlafaxine primarily inhibits
5-HT reuptake at lower clinical doses and only inhibits both NE and
5-HT reuptake at the highest clinical doses (Harvey et al., 2000;
Debonnel et al., 2007).
Duloxetine signiﬁcantly increased NE and 5-HT at all the doses
tested with an NE/5-HT ratio of approximately 1 at all doses. This is
A.L. Auclair et al. / Neuropharmacology 70 (2013) 338e347346consistent with the literature reporting signiﬁcant and comparable
increases in NE and 5-HT in the prefrontal cortex of rats following
acute administration of duloxetine (5 and 15 mg/kg ip; Koch et al.,
2003). Another study reported signiﬁcant increases in NE and 5-HT
in the prefrontal cortex following acute oral administration of
duloxetine (3e12 mg/kg and 6e12 mg/kg, respectively; Kihara and
Ikeda,1995). Doses of duloxetine below 10mg/kgwere not tested in
the present study, making true comparison of relative potency on
NE and 5-HT (as measured by MED) impractical.
In the present microdialysis studies, there was a plateauing ef-
fect for the increase in NE and 5-HT observed with LVM and
duloxetine. The reason(s) for this plateau for NE is not entirely clear,
but may be due in part to an increased activation of adrenergic
alpha2 autoreceptor-induced feedback inhibition of NE release,
which counterbalances the high levels of extracellular NE induced
by these drugs. Microdialysis studies in rats have shown that the
combined systemic treatment of desipramine (a selective NRI) with
idazoxan (an alpha2-adrenoceptor antagonist) results in a dramatic
potentiation of cortical NE output that is orders of magnitude
higher than the levels of NE attainable by either of these drug
treatments alone (Dennis et al., 1987). Similar autofeedback inhi-
bition effects have been described for the 5-HT system in the pre-
frontal cortex via activation of 5-HT1A receptors (Gartside et al.,
1995). It is unclear why a plateau effect was observed with dulox-
etine and LVM, but not venlafaxine, and additional experiments
(out of the scope of the present report) would be needed to resolve/
explore this matter.
All three SNRIs increased levels of DA; for duloxetine, this may
reﬂect a direct effect of blockade of DAT (Ki: 446 nM). However,
neither LVM nor venlafaxine have high afﬁnity for DAT; therefore,
increases in DA following LVM and venlafaxine administration is
most likely due to an indirect effect on DA via blockade of NET. In
the prefrontal cortex, where DA and NE terminals co-exist but NET
sites greatly outnumber DAT sites, NET is responsible for most
extracellular DA uptake (reviewed in El Mansari et al., 2010).
LVM, duloxetine, and venlafaxine were studied in two models
considered to be predictive of antidepressant-like activity: the
forced swim test (FST) and the tail suspension test (TST) (Porsolt
et al., 2001). Mice were selected for the FST because this species is
comparatively more sensitive than rats to the effects of SNRIs and
other classes of antidepressants (Castagne et al., 2009; in-house
unpublished data). In both models, LVM signiﬁcantly decreased the
timeof immobility.Whereas LVMhadadose-dependent effect in the
FST, it producedaU-shapeddoseeresponse curve in theTST. Reasons
for the U-shaped curve are unknown; however, they are unlikely to
be related tomotor-impairing/sedative effects, as LVMhadno impact
on spontaneous locomotor activity at similar doses in mice. The
difference of sensitivity of LVM between the FST and TST tests could
be related to the use of different strains (OF1 versus NMRI), as sug-
gested previously for other SNRIs (Kulkarni and Dhir, 2007).
Duloxetine and LVM had similar efﬁcacy and potency in the FST,
but LVM was more potent than duloxetine in the TST. The dulox-
etine effects observed in the TST and FST in the present study are in
agreement with those reported previously (Li et al., 2003;
Andreasen et al., 2009; Berrocoso and Mico, 2009a,b; Castagne
et al., 2009). Venlafaxine was less efﬁcacious and potent than
LVM and duloxetine in the FST, and only showed a moderate ten-
dency to reduce immobility in the TST. However, previous studies
have reported efﬁcacy of venlafaxine in each of these assays across
a similar dose range (Castagne et al., 2009). Lack of, or poor efﬁcacy
of venlafaxine in the present study could also be due to the use of
different strains.
LVM was also studied in the FST in comparison to MLN and
F2696. LVM differs in potency in these two sets of experiments. The
potency for LVM in the FST study in comparison with duloxetineand venlafaxine is lower than that in the MLN/LVM/F2696
comparative study. However, one should be cautious in directly
comparing these data, as the two sets of data were generated at
different times (two decades apart), in different strains obtained
from different breeders, and under slightly different conditions.
In the USV model in rats, “distress” calls in the 22 kHz range are
emitted in response to various stressful/aversive stimuli (such as
presentation of a conditioned stimulus previously associated with
mild foot shocks), and are considered to reﬂect an underlying
“anxiety-like/stress-like” affective state (Jelen et al., 2003). LVM
reduced USV, suggesting “anxiolytic-like” and/or “anti-stress” ef-
fects, and was approximately four times more potent than dulox-
etine. Venlafaxine was inactive in this assay, consistent with
previous reports (Sanchez, 2003). Previous studies have shown that
the SNRIs duloxetine and milnacipran are effective in the USV
model (Bardin et al., 2010); however, milnacipran (Bardin et al.,
2010) and LVM (present study) appear to have greater potency
than duloxetine in this assay. Perhaps the near 2-fold preference for
NE versus 5-HT reuptake inhibition properties of LVM and milna-
cipran confer an advantage of efﬁcacy in this model.
Taken together, the results from the FST, TST and USV models
clearly suggest a potential “antidepressant-like” and/or “anxiety/
anti-stress-like” activity of LVM, on the whole similar to that dis-
played by duloxetine, but apparently superior to that of venlafax-
ine. However, additional studies in these models following long-
term administration are warranted, as antidepressants are pre-
scribed on a chronic basis in the clinic; extrapolations from these
acute pre-clinical experiments to the clinic should be made with
caution. In addition, future studies should be conducted to evaluate
the efﬁcacy of LVM in models associated with NE-related depres-
sive symptoms (e.g. fatigue, anhedonia).
In summary, LVM is the pharmacologically more active enan-
tiomer of milnacipran. Like duloxetine and venlafaxine, it potently
inhibited NE and 5-HT reuptake in vitro, increased NE and 5-HT in
the rat prefrontal cortex, and like duloxetine, decreased immobility
in the FST and TST in mice (venlafaxine being, under our experi-
mental conditions, less or not active). However, LVM, unlike
duloxetine or venlafaxine, exhibited a 2-fold preference for NE over
5-HT reuptake inhibition in vitro, and to some extent in vivo (at the
lowest effective dose in the microdialysis study). At higher doses,
LVM, like duloxetine and venlafaxine, increased extracellular levels
of NE and 5-HT equally. Additional studies are needed to further
explore the relative potency of LVM on NE and 5-HT reuptake
in vivo and to determine the clinical relevance of this ﬁnding.
However, overall, these data demonstrate that LVM is a selective
and potent SNRI that may have potential therapeutic value in the
treatment of MDD.
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